Details of the Drug

General Information of Drug (ID: DMJGWZ7)

Drug Name
Eculizumab
Synonyms Eculizumab (intravitreal, AMD); Eculizumab (intravitreal, AMD), Alexion; Eculizumab (intravitreal, age-related macular degeneration), Alexion
Indication
Disease Entry ICD 11 Status REF
Age-related macular degeneration 9B75.0 Approved [1]
Neuromyelitis optica 8A43 Approved [2]
Paroxysmal nocturnal haemoglobinuria 3A21.0 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Affected Organisms
Humans and other mammals
ATC Code
L04AA25: Eculizumab
L04AA: Selective immunosuppressants
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Monoclonal antibody
Cross-matching ID
UNII
A3ULP0F556
DrugBank ID
DB01257
TTD ID
D01RQV
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HUMAN complement C5 protein (C5) TTN0GJ5 CO5_HUMAN Inhibitor [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6884).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017 May 18;3:17028.
4 ClinicalTrials.gov (NCT04346797) CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort
5 Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23.